CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

BofA analyst Alec Stranahan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $90 from $93 and keeps a Buy rating on the shares.

CRISPR Therapeutics (CRSP) shares closed at US$53.77 on Friday, with recent returns mixed, including a 2.5% gain over the past day but a weaker pattern over the month and the past 3 months. See our latest analysis for CRISPR Therapeutics.

CRISPR Therapeutics AG CRSP posted a loss for the first quarter on Tuesday. The company posted a quarterly loss of $1.58 per share, compared to market estimates of a loss of $1.21 per share. The company posted sales of $865,000. “CRISPR Therapeutics ...

Casgevy is now active across 35 Advanced Treatment Centres. Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end of the decade. CRSP remains highly shorted, with 20% of shares ...

CRISPR Therapeutics and Vertex Pharmaceuticals are partners in one particular program, and they recently won approval for the gene-editing treatment Casgevy. Beyond Casgevy, Vertex has a billion-dollar portfolio of products; Casgevy marks CRISPR ...

CRISPR Therapeutics is the first company to secure an FDA approval of a gene-editing drug. That drug's underlying science, however, could be used to create treatments for any number of genetically based diseases. Although rivals continue to work on ...

CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost. Despite no Q3 revenue from Casgevy, CRISPR maintains a ...

CRISPR Therapeutics is in the process of launching its first medicine. It has plenty of cash, no debt, and manageable expenses. It's also developing a slew of new candidates for other conditions. There are a handful of different factors that could buoy its ...